26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
6 citations
,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
1 citations
,
January 2025 in “American Journal of Translational Research” PPARα agonists may help treat alopecia areata by reducing inflammation.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
Baricitinib effectively regrows hair in severe alopecia areata cases.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
Baricitinib is more effective than methotrexate for severe alopecia areata.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
Combining epinephrine with a steroid may help regrow hair in severe alopecia areata cases.
April 2021 in “Sohag Medical Journal” Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” The model can effectively test gene functions and drug responses in human skin.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
November 2025 in “Frontiers in Immunology” SQSTM1 gene issues may increase the risk of alopecia areata.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.